Schizophrenia News and Research

Latest Schizophrenia News and Research

Scientists discover genetic cause of extreme thinness

Scientists have discovered a genetic cause of extreme thinness for the first time, in a study published today in the journal Nature.

2 Sep 2011

Older dads have a higher risk of having kids with mental disorders: Study

According to a new study children of older fathers have genetic changes associated with autism and other brain disorders. As of now this is seen only in lab mice. Professor John McGrath of the Queensland University’s Brain Institute and colleagues report their findings today in the journal Translational Psychiatry.

31 Aug 2011

Yoga as therapy in neuropsychiatric disorders

Yoga is commonly seen as a practice beneficial to body and mind. Increasingly, yoga is being taken a step further and applied as a form of complementary and alternative medicine in treating psychiatric disorders.

31 Aug 2011

Medicaid news: Texas Medicaid dental spending; Ill. providers hesitant on managed care

For the past six months, News 8 investigations have revealed hundreds of millions of dollars of questionable Medicaid spending on braces for children in Texas. Now federal investigators are auditing the Texas Health and Human Services Commission, which controls those funds. Taking the lead in the audit is the Office of Inspector General of the U.S. Department of Health and Human Services.

30 Aug 2011

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights.

29 Aug 2011

New insights into Lafora disease

Short-term energy storage in animal cells is usually achieved through the accumulation of glucose, in the form of long and branched chains, known as glycogen. But when this accumulation happens in neurons it is fatal, causing them to degenerate. This neuronal deterioration and death associated with glycogen accumulation is the hallmark of an extremely rare and progressive type of epilepsy known as Lafora disease (LD).

29 Aug 2011

Lundbeck Canada makes landmark donation of $2.7M to support depression research

Lundbeck Canada has made a landmark donation of $2.7 million to support ground-breaking research at the University Health Network to identify biomarkers that will enhance the diagnosis and treatment of patients suffering from major depression and bipolar disorder.

29 Aug 2011

Nurofen mix up with Seroquel schizophrenia drug warns MHRA

British drug regulators have issued a safety alert on Thursday after discovering packs of the over-the-counter painkiller Nurofen Plus containing the anti-psychotic drug Seroquel XL.

26 Aug 2011

Study reveals striking brain similarities in bipolar disorder and schizophrenia

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have conducted a study which has found striking brain similarities in bipolar disorder and schizophrenia. The research has also pinpointed for the first time that a process which controls how information is transmitted from neuron to neuron in the brain is altered in both conditions and may potentially contribute to the developments of improved treatments in the future.

25 Aug 2011

Tropical plants may contain basis of new and effective treatments for ovarian cancer

Tropical plants may contain the basis of new and effective treatments for ovarian cancer, according to researchers at the Universities of Strathclyde and Portsmouth.

25 Aug 2011

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

The classic symptoms of schizophrenia - paranoia, hallucinations, the inability to function socially-can be managed with antipsychotic drugs. But exactly how these drugs work has long been a mystery.

25 Aug 2011

People admitted to hospital for mental illness more likely to experience control intervention

The use of control interventions, including physical and mechanical restraints, acute control medications and seclusion, is intended to be a method of last resort in Ontario care facilities, including hospitals.

24 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Daily exercise can work as well as second antidepressant drug

Exercise can be as effective as a second medication for as many as half of depressed patients whose condition have not been cured by a single antidepressant medication.

24 Aug 2011

BioLineRx second quarter net loss decreases to NIS 16.4 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011.

23 Aug 2011

Harnessing the brain’s capacity to adapt and regenerate

Understanding the brain’s capacity to adjust to physical and mental trauma and injury – and how to exploit this therapeutically to help patients – is the focus of a major international symposium at the University of New South Wales next month (8 Sept).

22 Aug 2011

FDA accepts Alexza ADASUVE NDA, assigns PDUFA action date

Alexza Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has accepted the ADASUVE New Drug Application (NDA) as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.

20 Aug 2011